Background: Copeptin and nesfatin-1 have recently been identified as novel peptides that play a role in the pathogenesis of obesity-related insulin resistance in adults. However, the relationship between them has not yet been elucidated, and their circulating levels in children with obesity have not been adequately studied. Therefore, the current study aimed to investigate whether their levels are altered in Chinese children with obesity, as well as to determine the correlation of these 2 peptides with each other, with insulin resistance, and with other biochemical parameters. Methods: A total of 156 children were enrolled in this study, including 101 children with obesity and 55 lean controls. Anthropometric parameters and clinical data of all subjects were collected, and circulating tumor necrosis factor-α, adiponectin, leptin, copeptin, and nesfatin-1 levels were measured using ELISA. Results: Serum copeptin and nesfatin-1 levels were significantly elevated in children with obesity and children with insulin resistance compared to control subjects. In addition, nesfatin-1 and copeptin levels were found to be significantly positively correlated with one another by Pearson’s correlation and partial correlation. In multiple regression analysis using nesfatin-1 or copeptin as the dependent parameter, a significant correlation was observed between nesfatin-1 and copeptin, and associations between each of them with homeostasis model assessment of insulin resistance (HOMA-IR) were detected. Conclusion: These novel findings shed light on the possible interplay role of these 2 molecules in obesity-related insulin resistance.

1.
Reaven
GM
.
Insulin resistance and human disease: a short history
.
J Basic Clin Physiol Pharmacol
.
1998
;
9
(
2–4
):
387
406
.
2.
Silfen
ME
,
Denburg
MR
,
Manibo
AM
,
Lobo
RA
,
Jaffe
R
,
Ferin
M
, et al.
Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents
.
J Clin Endocrinol Metab
.
2003
;
88
(
10
):
4682
8
.
3.
Levy-Marchal
C
,
Arslanian
S
,
Cutfield
W
,
Sinaiko
A
,
Druet
C
,
Marcovecchio
ML
, et al.
Insulin resistance in children: consensus, perspective, and future directions
.
J Clin Endocrinol Metab
.
2010
;
95
(
12
):
5189
98
.
4.
Lee
JM
,
Okumura
MJ
,
Davis
MM
,
Herman
WH
,
Gurney
JG
.
Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study
.
Diabetes Care
.
2006
;
29
(
11
):
2427
32
.
5.
Caprio
S
,
Perry
R
,
Kursawe
R
.
Adolescent obesity and insulin resistance: roles of ectopic fat accumulation and adipose inflammation
.
Gastroenterology
.
2017
;
152
(
7
):
1638
46
.
6.
Solà
E
,
Kerbert
AJ
,
Verspaget
HW
,
Moreira
R
,
Pose
E
,
Ruiz
P
, et al.
Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis
.
J Hepatol
.
2016
;
65
(
5
):
914
20
.
7.
Barchetta
I
,
Enhörning
S
,
Cimini
FA
,
Capoccia
D
,
Chiappetta
C
,
Di Cristofano
C
, et al.
Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity
.
BMC Med
.
2019
;
17
(
1
):
85
.
8.
Riva
M
,
Nitert
MD
,
Voss
U
,
Sathanoori
R
,
Lindqvist
A
,
Ling
C
, et al.
Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects
.
Cell Tissue Res
.
2011
;
346
(
3
):
393
405
.
9.
Aydin
S
.
Multi-functional peptide hormone NUCB2/nesfatin-1
.
Endocrine
.
2013
;
44
(
2
):
312
25
.
10.
Stengel
A
,
Taché
Y
.
Role of brain NUCB2/nesfatin-1 in the regulation of food intake
.
Curr Pharm Des
.
2013
;
19
(
39
):
6955
9
.
11.
Ramesh
N
,
Mohan
H
,
Unniappan
S
.
Nucleobindin-1 encodes a nesfatin-1-like peptide that stimulates insulin secretion
.
Gen Comp Endocrinol
.
2015
;
216
:
182
9
.
12.
Khalili
S
,
Shekari Khaniani
M
,
Afkhami
F
,
Mansoori Derakhshan
S
.
NUCB2/Nesfatin-1: a potent meal regulatory hormone and its role in diabetes
.
Egypt J Med Hum Genet
.
2017
;
18
(
2
):
105
9
.
13.
Mohan
H
,
Unniappan
S
.
Ontogenic pattern of nucleobindin-2/nesfatin-1 expression in the gastroenteropancreatic tissues and serum of Sprague Dawley rats
.
Regul Pept
.
2012
;
175
(
1–3
):
61
9
.
14.
Enhörning
S
,
Wang
TJ
,
Nilsson
PM
,
Almgren
P
,
Hedblad
B
,
Berglund
G
, et al.
Plasma copeptin and the risk of diabetes mellitus
.
Circulation
.
2010
;
121
(
19
):
2102
8
.
15.
Rothermel
J
,
Kulle
A
,
Holterhus
PM
,
Toschke
C
,
Lass
N
,
Reinehr
T
.
Copeptin in obese children and adolescents: relationships to body mass index, cortisol and gender
.
Clin Endocrinol
.
2016
;
85
(
6
):
868
73
.
16.
Tenderenda-Banasiuk
E
,
Wasilewska
A
,
Filonowicz
R
,
Jakubowska
U
,
Waszkiewicz-Stojda
M
.
Serum copeptin levels in adolescents with primary hypertension
.
Pediatr Nephrol
.
2014
;
29
(
3
):
423
9
.
17.
Abaci
A
,
Catli
G
,
Anik
A
,
Kume
T
,
Bober
E
.
The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children
.
Pediatr Diabetes
.
2013
;
14
(
3
):
189
95
.
18.
Anwar
GM
,
Yamamah
G
,
Ibrahim
A
,
El-Lebedy
D
,
Farid
TM
,
Mahmoud
R
.
Nesfatin-1 in childhood and adolescent obesity and its association with food intake, body composition and insulin resistance
.
Regul Pept
.
2014
;
188
:
21
4
.
19.
Li
H
,
Ji
CY
,
Zong
XN
,
Zhang
YQ
.
[Body mass index growth curves for Chinese children and adolescents aged 0 to 18 years]
.
Zhonghua Er Ke Za Zhi
.
2009
;
47
(
7
):
493
8
.
20.
Tanner
JM
.
Assessment of growth and maturation during adolescence
.
Horm Res
.
1981
;
39
(
Suppl 3
):
9
17
.
21.
Prader
A
.
Testicular size: assessment and clinical importance
.
Triangle
.
1966
;
7
(
6
):
240
3
.
22.
Andrade
MI
,
Oliveira
JS
,
Leal
VS
,
Lima
NM
,
Costa
EC
,
Aquino
NB
, et al.
[Identification of cutoff points for Homeostatic Model Assessment for Insulin Resistance index in adolescents: systematic review]
.
Rev Paul Pediatr
.
2016
;
34
(
2
):
234
42
.
23.
Gallagher
EJ
,
LeRoith
D
,
Karnieli
E
.
Insulin resistance in obesity as the underlying cause for the metabolic syndrome
.
Mt Sinai J Med
.
2010
;
77
(
5
):
511
23
.
24.
Simpson
K
,
Parker
J
,
Plumer
J
,
Bloom
S
.
CCK, PYY and PP: the control of energy balance
.
Handb Exp Pharmacol
.
2012
;(
209
):
209
30
.
25.
Ramanjaneya
M
,
Chen
J
,
Brown
JE
,
Tripathi
G
,
Hallschmid
M
,
Patel
S
, et al.
Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity
.
Endocrinology
.
2010
;
151
(
7
):
3169
80
.
26.
Kim
S-H
,
Ahn
MB
,
Cho
WK
,
Cho
KS
,
Jung
MH
,
Suh
B-K
.
The relation of serum nesfatin-1 level with anthropometric and metabolic parameters in children and adolescents
.
Medicine
.
2019
;
98
(
19
):
e15460
.
27.
Pouliot
MC
,
Després
JP
,
Lemieux
S
,
Moorjani
S
,
Bouchard
C
,
Tremblay
A
, et al.
Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women
.
Am J Cardiol
.
1994
;
73
(
7
):
460
8
.
28.
Ashwell
M
,
Cole
TJ
,
Dixon
AK
.
Ratio of waist circumference to height is strong predictor of intra-abdominal fat
.
BMJ
.
1996
;
313
(
7056
):
559
60
.
29.
de Dios
O
,
Herrero
L
,
Gavela-Pérez
T
,
Soriano-Guillén
L
,
Garcés
C
.
Sex-specific association of plasma nesfatin-1 concentrations with obesity in children
.
Pediatr Obes
.
2019
;
14
(
12
):
e12567
.
30.
Bastard
JP
,
Maachi
M
,
Lagathu
C
,
Kim
MJ
,
Caron
M
,
Vidal
H
, et al.
Recent advances in the relationship between obesity, inflammation, and insulin resistance
.
Eur Cytokine Netw
.
2006
;
17
(
1
):
4
12
.
31.
Enhörning
S
,
Struck
J
,
Wirfält
E
,
Hedblad
B
,
Morgenthaler
NG
,
Melander
O
.
Plasma copeptin, a unifying factor behind the metabolic syndrome
.
J Clin Endocrinol Metab
.
2011
;
96
(
7
):
E1065
72
.
32.
Zhang
Z
,
Li
L
,
Yang
M
,
Liu
H
,
Boden
G
,
Yang
G
.
Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus
.
Exp Clin Endocrinol Diabetes
.
2012
;
120
(
2
):
91
5
.
33.
Tan
BK
,
Hallschmid
M
,
Kern
W
,
Lehnert
H
,
Randeva
HS
.
Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment
.
J Clin Endocrinol Metab
.
2011
;
96
(
4
):
E669
73
.
34.
Karbek
B
,
Ozbek
M
,
Karakose
M
,
Topaloglu
O
,
Bozkurt
NC
,
Cakır
E
, et al.
Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome
.
J Ovarian Res
.
2014
;
7
:
31
.
35.
Enhörning
S
,
Wang
TJ
,
Nilsson
PM
,
Almgren
P
,
Hedblad
B
,
Berglund
G
, et al.
Plasma copeptin and the risk of diabetes mellitus
.
Circulation
.
2010
;
121
(
19
):
2102
8
.
36.
Saleem
U
,
Khaleghi
M
,
Morgenthaler
NG
,
Bergmann
A
,
Struck
J
,
Mosley
TH
, et al.
Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome
.
J Clin Endocrinol Metab
.
2009
;
94
(
7
):
2558
64
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.